- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...
TAMPA, Fla., May 07, 2026--(BUSINESS WIRE)--Paradigm, a specialty care management organization focused on delivering value-based solutions to improve outcomes for patients, payers, and providers, ...
Le Bonheur Children's Hospital's risk-based innovation program Changing High-Risk Asthma in Memphis through Partnership (CHAMP) has significantly decreased health care use related to asthma by ...
Paradigm and Film2Future have inked a two-year collaborative agreement that will see the talent agency become the exclusive partner of the non-profit that promotes pathways into the entertainment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results